Abstracts tagged "Gout and inflammation"

Abstract Number: 1276 • 2018 ACR/ARHP Annual Meeting
Effect of Colchicine on Diabetes Incidence Among Gout Patients in a Veterans’ Affairs Population
Anastasia Slobodnick¹, Virginia Pike², Michael Toprover¹ and Michael Pillinger¹, ¹Medicine/Rheumatology, NYU School of Medicine, New York, NY, ²Medicine/Rheumatology, New York Harbor VA Healthcare System, New York, NY
Background/Purpose: Previous studies suggest that patients with gout are at increased risk for developing diabetes.1 One possible explanation for this increased risk is the activation…
Abstract Number: 1144 • 2017 ACR/ARHP Annual Meeting
Initiating Colchicine and Urate-Lowering Therapy Reduces Baseline Inflammation, and Improves Vascular Endothelial but Not Smooth Muscle Function in Gout Subjects: Resistance to Endothelial Improvement Among Patients with Cardiovascular Comorbidities
Talia Igel^1,2, Aaron Garza Romero², Virginia Pike³, Yu Guo⁴, Stuart Katz⁵, Binita Shah⁵, Irina Dektiarev⁵, Svetlana Krasnokutsky Samuels² and Michael Pillinger², ¹Medicine, Monash University School of Medicine, Melbourne, Australia, ²Medicine/Rheumatology, New York University School of Medicine, New York, NY, ³Medicine/Rheumatology, New York University School of Medicine, Division of Rheumatology, New York, NY, ⁴Population Health/Statistics, New York University School of Medicine, New York, NY, ⁵Medicine/Cardiology, New York University School of Medicine, New York, NY
Background/Purpose: We have previously reported that patients with gout have impaired vascular endothelial and smooth muscle responsiveness, but whether initiating appropriate gout therapy ameliorates these…
Abstract Number: 927 • 2014 ACR/ARHP Annual Meeting
Urate Crystal Induced Inflammation and Joint Pain Are Reduced in Transient Receptor Potential Ankyrin 1 (TRPA1) Deficient Mice – a New Potential Role for TRPA1 in Gout
Lauri J Moilanen, Mari Hämäläinen, Lauri Lehtimäki, Riina Nieminen and Eeva Moilanen, The Immunopharmacology Research Group, University of Tampere School of Medicine and Tampere University Hospital, Tampere, Finland
Background/Purpose: In the gout, monosodium urate (MSU) crystals deposit intra-articularly and cause painful arthritis. In the present study we tested the hypothesis that Transient Receptor…
Abstract Number: 2743 • 2013 ACR/ARHP Annual Meeting
Targeted Activation Of The Metabolic Super-Regulator AMP-Activated Protein Kinase (AMPK) Blunts Gouty Inflammation
Ru L. Bryan¹, Robert Terkeltaub² and Yun Wang³, ¹Medicine-Rheumatology, VA Medical Center/University of California San Diego, San Diego, CA, ²Medicine-Rheumatology, VA Medical Ctr/University of California San Diego, San Diego, CA, ³Medicine-Rheumatology, VA Medical Ctr/UCSD, San Diego, CA
Background/Purpose: Gout is associated with both multiple dietary triggers and metabolic co-morbidities, including obesity, metabolic syndrome, and diabates. AMP-activated protein kinase (AMPK) is a master…
Abstract Number: 1986 • 2013 ACR/ARHP Annual Meeting
Colchicine Use and The Risk Of Myocardial Infarction Among Gout Patients: Results From a Community-Based, Informatics-Driven Retrospective Cohort Study
Daria B. Crittenden¹, Binita Shah², Steven P. Sedlis², Christopher J. Swearingen³, Eric S. Wagner⁴, Yvette M. Henry⁴, Peter B. Berger⁴, Bruce N. Cronstein¹ and Michael H. Pillinger⁵, ¹Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY, ²NYU School of Medicine, Division of Cardiology, New York, NY, ³Pediatric Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, ⁴Geisinger Health System, Cardiovascular Center for Clinical Research, Danville, PA, ⁵NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose: Gout patients have an increased risk of myocardial infarction (MI). Since atherosclerosis and plaque rupture are inflammatory processes, anti-inflammatory gout medications might also reduce…
Abstract Number: 1179 • 2013 ACR/ARHP Annual Meeting
Colchicine Use and The Risk Of Myocardial Infarction Among Gout Patients: Interim Results From a VA Retrospective Cohort Study
Daria B. Crittenden¹, Jessica N. Kimmel¹, Virginia C. Pike¹, Daniel Diaz¹, Avni Shah², Cilian J. White¹, Michael DeBerardine², Grace Kim², Binita Shah³, Christopher J. Swearingen⁴, Jeffrey D. Greenberg⁵, Steven P. Sedlis³, Craig T. Tenner⁶, Bruce N. Cronstein¹ and Michael H. Pillinger², ¹Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY, ²NYU School of Medicine, Division of Rheumatology, New York, NY, ³NYU School of Medicine, Division of Cardiology, New York, NY, ⁴Pediatric Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, ⁵Division of Rheumatology, Department of Medicine, NYU Hospital for Joint Diseases, New York, NY, ⁶Internal Medicine, NYU School of Medicine, Department of Internal Medicine, New York, NY
Background/Purpose: Gout patients are at increased cardiovascular (CV) risk. Since atherosclerosis is an inflammatory process, anti-inflammatory strategies to reduce CV risk are currently being investigated.…
Abstract Number: 1161 • 2013 ACR/ARHP Annual Meeting
Microrna-155 As a Proinflammatory Regulator via SHIP-1 Down-Regulation In Acute Gouty Arthritis
Hye Mi Jin¹, Young-Nan Cho¹, Seung-Jung Kee², Dong-Jin Park³, Yong-Wook Park³, Shin-Seok Lee⁴ and Tae-Jong Kim¹, ¹Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea, ²Laboratory Medicine, Chonnam National University Medical School and Hospital, Gwangju, South Korea, ³Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ⁴Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea
Background/Purpose: Gout is characterised by episodes of intense joint inflammation in response to intra-articular monosodium urate monohydrate (MSU) crystals. miR-155 is crucial for the proinflammatory…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].